|
시장보고서
상품코드
2035515
의약품 개발 및 제조 수탁 기관(CDMO) 아웃소싱 시장 규모, 점유율, 성장 분석 : 서비스 유형별, 용도별, 지역별 - 업계 예측(2026-2033년)Contract Development And Manufacturing Organization Outsourcing Market Size, Share, and Growth Analysis, By Service Type, By Application, By Region - Industry Forecast 2026-2033 |
||||||
세계의 의약품 개발 및 제조 수탁 기관(CDMO) 아웃소싱 시장 규모는 2024년에 2,433억 6,000만 달러로 평가되었고, 2025년 2,589억 4,000만 달러에서 2033년까지 4,253억 3,000만 달러로 성장하고, 예측 기간(2026-2033년)에 CAGR 6.4%를 보일 전망입니다.
세계 의약품 CDMO(위탁개발 및 제조)아웃소싱 시장은 제약업계의 의약품 개발 및 제조에 대한 접근 방식에 있어 중요한 전환을 보여주고 있습니다. 제약회사는 CDMO와 협력함으로써 프로세스를 효율화하고, 대규모 사내 시설을 구축할 필요 없이 혁신적 치료법에 대한 수요 증가에 대응할 수 있습니다. 현재 CDMO는 의약품 연구, 전임상 및 임상시험 지원, 유효성분(API) 제조, 제형 개발 등의 종합적인 서비스군을 제공하고 있으며, 연구부터 상업화까지 전체 가치사슬을 아우르고 있습니다. 제약기업, 특히 중소규모의 기업들이 의약품 개발 및 제조의 복잡성 증가에 직면하면서 CDMO에 대한 아웃소싱 수요가 크게 증가하여 업계 상황을 형성할 것으로 예측됩니다.
세계 의약품 CDMO(위탁개발 및 제조)아웃소싱 시장 활성화 요인
세계 의약품 CDMO(위탁개발 및 제조)아웃소싱 시장은 만성질환의 유병률 증가로 인해 크게 견인되고 있습니다. 이는 주로 서유럽화된 라이프스타일의 확산, 경제 성장, 인구 증가의 영향을 받고 있습니다. 인구의 상당수가 만성 질환을 앓고 있고, 전 세계적으로 수백만 명이 영향을 받고 있어 헬스케어 솔루션에 대한 수요가 증가하고 있습니다. 만성질환이 보편화되고 지속적인 관리가 필요한 경우가 늘어남에 따라 효율적인 위탁 개발 및 제조 서비스의 필요성은 필수 불가결한 요소가 되고 있습니다. 이러한 추세는 헬스케어 수요에 대응하기 위해 제약 및 생명공학 분야를 지원하는 CDMO의 중요한 역할을 강조하고 있습니다.
세계 의약품 CDMO(위탁개발 및 제조)아웃소싱 시장의 제약 조건
세계 의약품 CDMO(위탁개발 및 제조)아웃소싱 시장의 성장을 저해하는 몇 가지 과제가 예상됩니다. 엄격한 정부 규제는 업무의 유연성을 크게 제한할 수 있으며, 선진국의 각종 저분자 의약품 및 생물학적 제제의 승인률 감소는 시장 상황을 더욱 복잡하게 만들고 있습니다. 또한, 첨단 기술이나 설비가 부족한 소규모 CDMO는 공정상의 오류나 품질 편차 등의 문제에 직면하는 경우가 많으며, 그 결과 비용 증가와 비효율성을 초래하고 있습니다. 이러한 요인들이 복합적으로 작용하여 가까운 미래에 CDMO 시장의 전반적인 확대와 발전을 제한하는 장벽이 될 것으로 예측됩니다.
세계 의약품 개발 및 제조수탁기관(CDMO) 아웃소싱 시장 동향
제약사들이 의약품 개발 프로세스를 효율화하기 위해 혁신적이고 효율적인 솔루션을 점점 더 많이 찾고 있는 가운데, 세계 의약품 CDMO(위탁개발 및 제조)아웃소싱 시장에서는 통합과 제휴를 향한 뚜렷한 변화가 나타나고 있습니다. 이러한 추세는 다양한 바이오 의약품의 요구에 부응하는 맞춤형 서비스에 대한 수요 증가에 따라 CDMO 업체들은 신생 바이오테크놀러지 기업 및 전통적 제약사들과 전략적 제휴를 모색하고 있습니다. 이러한 제휴는 서비스 제공의 확대뿐만 아니라 신속한 혁신과 비용 효율적인 제조 솔루션의 실현을 촉진하고, CDMO가 의약품 개발 라이프사이클을 가속화하고 생명과학 분야의 진화하는 요구사항에 대응하는 데 있어 매우 중요한 역할을 할 수 있도록 지원합니다. 라고 말했습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 의약품 개발 및 제조 수탁 기관(CDMO) 아웃소싱 시장 규모 : 서비스 유형별
세계의 의약품 개발 및 제조 수탁 기관(CDMO) 아웃소싱 시장 규모 : 용도별
세계의 의약품 개발 및 제조 수탁 기관(CDMO) 아웃소싱 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSHGlobal Contract Development And Manufacturing Organization (CDMO) Outsourcing Market size was valued at USD 243.36 Billion in 2024 and is poised to grow from USD 258.94 Billion in 2025 to USD 425.33 Billion by 2033, growing at a CAGR of 6.4% during the forecast period (2026-2033).
The market for global Contract Development and Manufacturing Organizations (CDMOs) highlights a pivotal shift in the pharmaceutical industry's approach to drug development and production. By collaborating with CDMOs, pharmaceutical companies can streamline the process, avoiding the need for extensive in-house facilities while responding to the growing demand for innovative therapies. CDMOs now offer a comprehensive suite of services that includes drug research, preclinical and clinical trial support, active pharmaceutical ingredient (API) production, and dosage form development, covering the entire value chain from research to commercialization. As pharmaceutical companies, particularly smaller firms, grapple with the increasing complexity of drug development and manufacturing challenges, the demand for CDMO outsourcing is expected to experience significant growth, shaping the future landscape of the industry.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contract Development And Manufacturing Organization (CDMO) Outsourcing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Segments Analysis
Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market is segmented by Service Type, Application and region. Based on Service Type, the market is segmented into Contract Development, Contract Manufacturing, Integrated CDMO Services and Others. Based on Application, the market is segmented into Oncology, Infectious Diseases, Cardiovascular Diseases, Neurology and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market
The Global Contract Development and Manufacturing Organization (CDMO) Outsourcing market is significantly driven by the increasing prevalence of chronic diseases, which is largely influenced by the adoption of a westernized lifestyle, economic growth, and population growth. A substantial portion of the population grapples with chronic illnesses, with millions affected globally, leading to a greater demand for healthcare solutions. As chronic conditions become more common and often require ongoing management, the need for efficient contract development and manufacturing services becomes imperative. This trend underscores the critical role of CDMOs in supporting the pharmaceutical and biotechnology sectors in addressing healthcare demands.
Restraints in the Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market
Several challenges are poised to hinder the growth of the Global Contract Development and Manufacturing Organization (CDMO) outsourcing market. Stringent government regulations can significantly restrict operational flexibility, while a decrease in the approval rates for various small molecules and biologics in advanced economies further complicates the landscape. Moreover, smaller CDMOs that lack advanced technology and equipment often face issues related to process errors and inconsistent quality, leading to higher costs and inefficiencies. Collectively, these factors are expected to create barriers that may limit the overall expansion and development of the CDMO market in the foreseeable future.
Market Trends of the Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market
The Global Contract Development and Manufacturing Organization (CDMO) outsourcing market is experiencing a notable shift towards consolidation and collaboration as pharmaceutical companies increasingly seek innovative, efficient solutions to streamline drug development processes. This trend is driven by the rising demand for tailored services that cater to diverse biopharmaceutical needs, prompting CDMOs to form strategic partnerships with both emerging biotech firms and established pharmaceutical giants. These collaborations not only enhance service offerings but also facilitate rapid innovation and cost-effective manufacturing solutions, positioning CDMOs as pivotal players in accelerating the drug development lifecycle and meeting the evolving requirements of the life sciences sector.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size by Service Type & CAGR (2026-2033)
- Market Overview
- Contract Development
- Contract Manufacturing
- Integrated CDMO Services
- Others
Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size by Application & CAGR (2026-2033)
- Market Overview
- Oncology
- Infectious Diseases
- Cardiovascular Diseases
- Neurology
- Others
Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size & CAGR (2026-2033)
- North America (Service Type, Application)
- US
- Canada
- Europe (Service Type, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Service Type, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Service Type, Application)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Service Type, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Lonza Group AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Catalent, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi AppTec Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Biologics Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Recipharm AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fareva Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siegfried Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Almac Group Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Evotec SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cambrex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Piramal Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Jubilant Pharmova Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Curia Global, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PCI Pharma Services
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vetter Pharma-Fertigung GmbH & Co. KG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aenova Group GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CordenPharma International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujifilm Diosynth Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
